2004Chinese Clinical OncologyRequires access

A study of weekly paclitaxel/cisplatin combined with 5-fluorouracil/Leucovorin(5-Fu/LV)as second-line chemotherapy for the patients with advanced gastric cancer(AGC)

Hongjun Lu

Open publisher page 0 citations

Abstract

Objective:To evaluate the efficacy of weekly paclitaxel,cisplatin combined with continuous infusion 5-fluorouracil/Leucovorin as second-line chemotherapy in patients with AGC.Methods:A total of 36 patients were included in our study,treated with weekly paclitaxel,cisplatin combined with continuous infusion 5-fluorouracil/Leucovorin;Efficacy and toxicity were evaluated after 2~3 cycles.Results:Of 36 assessable casses,two received a complete remission,and 13 patients received partial remission,with a overall response rate of 41.6%.Main toxicities were marrow suppression and trichomadesis,most of the patients were in good tolerance.Conclusion:weekly paclitaxel,cisplatin combined with continuous infusion 5-fluorouracil/Leucovorin as second line chemotherapy was a considerable regimen in patients with AGC.

About this research paper

What this paper is about

Objective:To evaluate the efficacy of weekly paclitaxel,cisplatin combined with continuous infusion 5-fluorouracil/Leucovorin as second-line chemotherapy in patients with AGC.Methods:A total of 36 patients were included in our study,treated with weekly paclitaxel,cisplatin combined with continuous infusion 5-fluorouracil/Leucovorin;Efficacy and toxicity were evaluated after 2~3 cycles.Results:Of 36 assessable casses,two received a complete remission,and 13 patients received partial remission,with a overall response rate of 41.6%.Main toxicities were marrow suppression and trichomadesis,most of the patients were in good tolerance.Conclusion:weekly paclitaxel,cisplatin combined with continuous infusion 5-fluorouracil/Leucovorin as second line chemotherapy was a considerable regimen in patients with AGC.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To evaluate the efficacy of weekly paclitaxel,cisplatin combined with continuous infusion 5-fluorouracil/Leucovorin as second-line chemotherapy in patients with AGC.Methods:A total of 36 patients were included in our study,treated with weekly paclitaxel,cisplatin combined with continuous infusion 5-fluorouracil/Leucovorin;Efficacy and toxicity were evaluated after 2~3 cycles.Results:Of 36 assessable casses,two received a complete remission,and 13 patients received partial remission,with a overall response rate of 41.6%.Main toxicities were marrow suppression and trichomadesis,most of the patients were in good tolerance.Conclusion:weekly paclitaxel,cisplatin combined with continuous infusion 5-fluorouracil/Leucovorin as second line chemotherapy was a considerable regimen in patients with AGC.

Key concepts: Medicine, Fluorouracil, Cisplatin, Paclitaxel, Chemotherapy, Regimen, Internal medicine, Gastroenterology

Back to paper searchBrowse research topicsOriginal source
A study of weekly paclitaxel/cisplatin combined with 5-fluorouracil/Leucovorin(5-Fu/LV)as second-line chemotherapy for the patients with advanced gastric cancer(AGC) — Research Paper | ScholarLens